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Background: The antiestrogen tamoxifen may have partial estrogen-like effects on the postmenopausal uterus.
Aromatase inhibitors (AIs) are increasingly used after initial tamoxifen in the adjuvant treatment of postmenopausal
early breast cancer due to their mechanism of action: a potential beneﬁt being a reduction of uterine abnormalities
caused by tamoxifen.
Patients and methods: Sonographic uterine effects of the steroidal AI exemestane were studied in 219 women
participating in the Intergroup Exemestane Study: a large trial in postmenopausal women with estrogen receptor-
positive (or unknown) early breast cancer, disease free after 2–3 years of tamoxifen, randomly assigned to continue
tamoxifen or switch to exemestane to complete 5 years adjuvant treatment. The primary end point was the proportion of
patients with abnormal (‡5 mm) endometrial thickness (ET) on transvaginal ultrasound 24 months after randomisation.
Results: The analysis included 183 patients. Two years after randomisation, the proportion of patients
with abnormal ET was signiﬁcantly lower in the exemestane compared with tamoxifen arm (36% versus
62%, respectively; P = 0.004). This difference emerged within 6 months of switching treatment (43.5% versus
65.2%, respectively; P = 0.01) and disappeared within 12 months of treatment completion (30.8% versus 34.7%,
respectively; P = 0.67).
Conclusion: Switching from tamoxifen to exemestane signiﬁcantly reverses endometrial thickening associated with
continued tamoxifen.
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introduction
Tamoxifen, for many years the ‘gold-standard’ endocrine
treatment of breast cancer, is associated with an increased
incidence of uterine abnormalities such as endometrial
hyperplasia, polyps, cysts and ﬁbroids and an increased risk of
uterine cancer and sarcoma [1, 2]. These effects are thought to
be related to the agonistic pathway elicited by tamoxifen on
uterine estrogen receptors.
Data from the Early Breast Cancer Trialists’
Collaborative Group overview [3] indicate that the
incidence of uterine cancer in patients with primary breast
cancer receiving adjuvant tamoxifen is increased by
af a c t o ro f3 (1.9 versus 0.6 per 1000 per year). Although
the absolute risk of endometrial cancer in patients under
tamoxifen is low, screening programmes using transvaginal
ultrasound (TVUS) have been proposed [4]. In
postmenopausal women, an endometrial lining measuring
<5 mm is considered an accurate cut-off in excluding
endometrial disease. Abnormal endometrial thickness (ET)
i.e. ‡5 mm occurs in 8% of asymptomatic postmenopausal
women [5] but has been reported in up to 85% of
asymptomatic postmenopausal breast cancer patients on
tamoxifen [6–13]. Following tamoxifen discontinuation,
ET tends to decrease [14] but in some patients abnormal
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16] have reported abnormal thickness in 45% and 42% of
patients after 12 and 30 months, respectively, from
withdrawal of tamoxifen.
The relationship between ET and the presence of endometrial
pathological abnormality varies, but most investigators agree
that endometrial thickening has low speciﬁcity and low positive
predictive value for histological abnormalities in tamoxifen-
treated patients [9]. This effect is mainly due to tamoxifen-
induced subepithelial stromal proliferation, entrapping gland
lumens leading to cystic changes. This anatomical condition
mimics endometrial hyperplasia at ultrasound, while the
epithelium remains normal or atrophic in the majority of cases
[17]. Such false-positive results, in a population known to be at
risk for uterine cancer, may generate stress and anxiety among
patients and clinicians and lead to unnecessary invasive
procedures. Based on the limited availability of efﬁcacious or
cost-effective diagnostic tests, the American College of
Obstetricians and Gynaecologists recommends routine yearly
gynaecological examination with further evaluation limited to
patients presenting with bleeding or vaginal discharge [18].
Despite this, active surveillance for endometrial pathological
abnormalities is commonly practised among tamoxifen users
[19].
Aromatase inhibitors (AIs) are a class of compounds that
inhibit the synthesis of estrogens from androgens. Third-
generation nonsteroidal inhibitors (anastrozole and letrozole)
and the steroidal inactivator exemestane induce >98%
inhibition of whole-body aromatisation [20, 21] and have been
shown to outperform tamoxifen as adjuvant therapy in
postmenopausal women with early breast cancer [22–24].
Additionally, due to the lack of estrogenic activity, a potential
advantage of their use in this setting might be the lack of
adverse uterine effects.
The Intergroup Exemestane Study (IES) compared
continued tamoxifen with a switch to exemestane after 2–3
years of tamoxifen to complete a total of 5 years treatment
in postmenopausal women with early breast cancer.
Improvements in disease-free and overall survival in patients
who switched to exemestane have been reported [24, 25].
Improvements were achieved without compromising overall
quality of life [26], and with limited detrimental effects on
skeletal health [27]. While major gynaecological safety data
were collected, uterine effects in asymptomatic patients could
be overlooked. A sub-protocol was therefore designed to
allow prospective assessment of uterine changes in a subset
of IES participants. As all patients were postmenopausal and
had been exposed to tamoxifen for 2–3 years, a high
incidence of baseline abnormality was expected. Results of
this sub-protocol up to 24 months after treatment, along
with the incidence of gynaecological events in the main trial,
are presented here.
patients and methods
study design
IES was an international double-blind phase III randomised trial
conducted by the International Collaborative Cancer Group (ICCG)
under the auspices of the Breast International Group. From 1998 to
2003, 4724 postmenopausal women previously diagnosed with
estrogen receptor-positive or estrogen receptor-unknown breast
cancer who received adequate local and adjuvant treatments and
r e m a i n e dd i s e a s ef r e ea f t e r2 – 3y e a r so ft a m o x i f e nw e r ec e n t r a l l y
randomly assigned to either continue tamoxifen (20 mg/day) or
switch to exemestane (25 mg/day) to complete a total of 5 years
adjuvant endocrine therapy [24, 25]. The endometrial sub-protocol
was implemented in 26 of the 366 IES centres. The institutional
review board or local ethics committee at each participating centre
approved the sub-protocol.
eligibility criteria
The eligibility criteria for the main study have been previously described
[24]; brieﬂy, patients were postmenopausal (‡55 years of age with
amenorrhoea for >2 years or amenorrhoea for >1 year at the time of
diagnosis) and had received adjuvant tamoxifen for at least 2 years but not
>3 years and 1 month. Patients were excluded if they had used hormone
replacement therapy (HRT) within 4 weeks before randomisation and if
they were taking any other form of hormone therapy other than tamoxifen.
Additionally, patients were eligible for the endometrial sub-protocol if they
had an intact uterus and signed informed consent to participate in the sub-
protocol. Patients with abnormal vaginal bleeding during the previous year
were eligible if uterine malignancy had been adequately excluded by
hysteroscopy and/or biopsy.
endometrial assessments
Patients underwent baseline TVUS in the month before randomisation.
Follow-up examinations (including TVUS) were repeated in parallel to
main study visits (64 weeks) at months 6, 12, 24 and end of treatment
(EoT). TVUS examinations at 12 and 24 months after treatment
completion were added following a protocol amendment (May 2001).
TVUS was also carried out at disease recurrence. The EoT
examination could be omitted if within 6 months of a previous
endometrial assessment.
ET and uterine volume were measured from the TVUS. The
anteroposterior measurement of ET was obtained from the longitudinal
axis view at the widest point of the endometrial–myometrial interface,
recording the maximum width of the double layer (excluding anechoic
endometrial ﬂuid collection). The maximum longitudinal diameter
(length) of the uterus was measured from the internal os to the fundus
(D1). The largest diameters in the transverse (D2) and the
anteroposterior (D3) planes were also recorded. Uterine volume was
estimated as (D1 · D2 · D3)/2. Hard copies of all available TVUS scans
were subject to independent review by a gynaecologist experienced in pelvic
sonography.
study end points
The primary end point was the proportion of patients with ET ‡5m ma t2 4
months after randomisation. Secondary end points included the proportion
of patients with ET ‡5 mm at 6 and 12 months after randomisation and 12
and 24 months after EoT, ET as a continuous variable and uterine volume.
Incidence of gynaecological symptoms, gynaecological procedures and
serious gynaecological adverse events (AEs) were recorded as part of the
main trial.
statistical considerations
The sample size was based on estimates of the proportion of
postmenopausal patients with ET in women undergoing tamoxifen
treatment and those undergoing no hormonal therapy. Target accrual was
initially 114 patients to detect a 30% absolute difference in the proportion
of patients with ET ‡5 mm 24 months after randomisation (from 50% in
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a two-sided signiﬁcance level of 0.05.
Data on ET following cessation of tamoxifen [16] published in 2000 led
the Trial Steering Committee (TSC) to re-evaluate these estimates and
the sample size was increased to 176 patients (200 allowing for a 15%
attrition rate) in order to detect a 25% difference in the proportion of
patients with ET ‡5 mm (i.e. from 55% in the tamoxifen group to 30% in
the exemestane group). The study has 73% power to detect such
a difference based on the number of patients assessable for the primary
end point.
Analyses were conducted on complete data, cleaned and processed by the
ICCG Coordinating Data Centre (CDC), available on 26 November 2006 by
use of Stata (version 9.2).
The primary comparison was based on patients who received at
least 24 months of allocated treatment and underwent TVUS 22–26 months
after randomisation (denoted assessable for primary end point
population). All other analyses were carried out on all randomised
patients on an intention-to-treat (ITT) basis. Participants were censored
at hysterectomy and relapse. TVUS was only included at particular visits
if it fell within the predeﬁned windows based on the date of TVUS. If
the EoT examination was not carried out as it fell within 6 months
of a previous visit, the 24-month TVUS was included as the EoT
assessment.
Sensitivity analyses were carried out on the following populations:
eligible patients only (i.e. excluding patients subsequently found to be
ineligible for either the main trial or the sub-protocol); all treated patients;
patients evaluable for the primary endpoint; and all patients assessed within
tighter visit windows. These sensitivity analyses (not shown) conﬁrmed the
robustness of the primary analysis.
Differences in proportions between the two groups were compared using
chi-square and Fisher’s exact test as appropriate. One-sample paired t-tests
were used to assess within-group changes in ET and uterine volume at each
time point expressed as changes from baseline. Differences in mean changes
(exemestane–tamoxifen) of these measures (where negative values indicate
greater change in the tamoxifen group than in the exemestane group)
were compared using two-sample t-tests. All analyses used a 5%
signiﬁcance level.
To account for the longitudinal nature of the ET data, a linear mixed
model was ﬁtted adjusting for randomised treatment, baseline ET and
weight and timing of TVUS with consideration given to interactions and
polynominal effects. The overall interpretation of the results was not
altered. For simplicity, and to aid clinical review, results based on changes
from baseline are reported.
The incidences of gynaecological and menopausal AEs in the main study
were compared by treatment group. On-treatment analysis included AEs
occurring between randomisation and 30 days after last study treatment,
censoring patients at time of relapse or second primary cancer. AEs are
presented if the incidence was ‡10% in either treatment group, if the
difference between the groups was >1% or if the difference between the
treatment groups was signiﬁcant at the 1% level.
role of the funding source
The sub-protocol was developed by the IES TSC. The sponsor provided
funding, had limited input in the study design and gave organisational and
monitoring support to the CDC where the database was independently
held. Transfers of frozen copies of the database were provided to the
sponsor for submission to the regulatory authorities and fulﬁlment of
regulatory responsibilities. All members of the TSC, including sponsor
representatives, were given the opportunity to critically review the
manuscript; however, editorial control was retained by the members of the
steering committee independent of the sponsor. All analyses were
conducted by the CDC in agreement with the trial’s Independent Data
Monitoring Committee and TSC. The corresponding author had access to
all study data and took ﬁnal responsibility for the decision to submit for
publication.
results
From 1999 to 2001, 219 patients (104 exemestane and 115
tamoxifen) were enrolled into the endometrial sub-protocol
(Figure 1). Monitoring carried out by the sponsor highlighted
a number of issues at one endometrial sub-protocol satellite
site and the data were considered unreliable. All 36 patients
from this site (17 exemestane and 19 tamoxifen) were
therefore excluded from the analysis leaving 183 patients (87
exemestane and 96 tamoxifen) in the ITT population
(including three patients who did not receive any treatment).
Two patients were subsequently found to be protocol violators
b e c a u s et h e yd i dn o th a v eb a s e l i n eT V U Sc a r r i e do u tw i t h i n
30 days before randomisation but are included in the analyses
presented here. The primary comparison included 117
assessable patients.
TVUS scans for 89.7% study assessments were independently
reviewed and, following a query to the local investigator, 11.3%
of original ET measurements were amended.
At baseline, the two groups were well balanced with regard to
demographic characteristics and prior treatment (Table 1), ET
and uterine volume (Table 2). Gynaecological symptoms
during tamoxifen treatment before randomisation were
reported in 20% of women (18 exemestane and 19 tamoxifen).
The overall median ET at baseline (randomisation) was 6.0 mm
(inter-quartile range 3.5–9.0) and 62.6% of patients had
increased (‡5 mm) ET.
Twenty-four-month TVUS scans were available for 117
(85%) of randomised patients who received at least 2 years of
allocated treatment. ET ‡5 mm was found in 35.5% [95%
conﬁdence interval (CI) 23.6% to 47.4%] of patients switched
to exemestane and in 61.8% (95% CI 49.0% to 74.7%) of those
continuing tamoxifen (P = 0.004; Table 3). The difference in
the proportion of patients with abnormal ET had emerged by 6
months after randomisation (43.5% exemestane versus 65.2%
tamoxifen; P = 0.01) and persisted throughout the protocol
treatment period. Within 12 months of treatment completion,
there were no differences in the proportion of patients with
abnormal ET (30.8% exemestane versus 34.7% tamoxifen;
P = 0.67).
A within-patient transition from abnormal ET at baseline
to normal thickness after 24 months of allocated treatment
w a so b s e r v e di n2 0p a t i e n t s( 53%) switched to exemestane
and in six patients (19%) continuing tamoxifen (Table 4).
Among patients with normal ET at baseline, four patients
(17%) in the exemestane group and eight (35%) in the
tamoxifen group developed endometrial thickening.
Additional gynaecological investigations were not mandated
by the protocol; therefore, we cannot correlate these changes
in endometrial thickening with hysteroscopy or biopsy
results.
Patients who switched to exemestane had a rapid
decrease of ET in the ﬁrst 6 months (mean change from
baseline 21.9 mm; 95% CI 23.1 to 20.6; P = 0.003;
original article Annals of Oncology
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observed between 6 and 24 months (mean change 24–6
months = 20.4 mm; 95% CI 21.3 to 0.5; P = 0.37).
Patients who continued on tamoxifen had no signiﬁcant
changes of ET from baseline to 24 months after
randomisation. At 12 and 24 months after EoT, no
difference was observed between the two treatment groups
in mean change from baseline.
Uterine volume was signiﬁcantly reduced after 6 months in
patients switching to exemestane (mean change from
baseline 215.3 cm
3; 95% CI 222.4 to 28.2; P = 0.0001) while
remaining similar in the tamoxifen group (mean change = 21.8
cm
3;9 5 %C I26.2 to 2.5; P = 0.40; Figure 2B). In consequence,
6 months after randomisation, the difference in mean
change between the two treatment groups (213.5 cm
3;9 5 %
CI 221.7 to 25.2) was highly signiﬁcant (P = 0.002). Again, the
observed difference was maintained after 12 and 24 months, with
difference in mean changes of 222.1 cm
3 (95% CI 232.8 to
211.4; P = 0.0001) and 218.9 cm
3 (95% CI 230.4 to 27.5;
P = 0.001), respectively. Mean change from baseline in uterine
4724 patients in IES
219 enrolled into the
endometrial sub-protocol 
183 available
patients 
ITT analysis
population
87 randomised to
exemestane 
96 randomised
to tamoxifen
 
17 unevaluable ¥ 19 unevaluable ¥
All treated
population
86 received
exemestane
  94 received
tamoxifen
 
1 not treated 2 not treated
71 completed
exemestane
treatment 
66 completed
exemestane
treatment 
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- 7 recurrence
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- 1 adverse event
- 1 lost to follow up
 
1 ineligible *
28 withdrawn from
treatment 
15 withdrawn from
treatment 
- 16 recurrence
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endpoint population
62 with at least
24 months
treatment &
TVUS at 24
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55 with at least
24 months
treatment &
TVUS at 24
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9 did not have 24
month TVUS 
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month TVUS
 
Figure 1. Consolidated standards of reporting trials diagram.
UMonitoring carried out by the sponsor highlighted a number of issues regarding the conduct
of the endometrial sub-protocol at a satellite site. Based on these ﬁndings, patients at this satellite site have been excluded from the endometrial sub-protocol
analysis (n = 36). *TVUS not carried out £30 days before randomisation. These patients were included in the analyses presented here. TVUS, transvaginal
ultrasound; IES, Intergroup Exemestane Study; ITT, intention-to-treat.
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12 months after EoT (216 cm
3;9 5 %C I228.7 to 23.3;
P = 0.01) but no signiﬁcant difference was seen 24 months
after EoT.
Eight patients in the endometrial substudy (exemestane
two and tamoxifen six) underwent hysterectomy
(6salpingo-oophorectomy): one (tamoxifen) due to second
primary ovarian cancer, three due to cervical cancer
(exemestane two, tamoxifen one) and four (on tamoxifen)
due to other gynaecologicals y m p t o m ss u c ha sc o m p l e x
endometrial hyperplasia, ﬁbroids and polyps. No
endometrial cancers were reported in the sub-protocol
population.
In the main IES trial, endometrial hyperplasia, uterine
polyps/ﬁbroids, uterine dilation and curettage and vaginal
bleeding had a signiﬁcantly higher incidence on treatment in
the tamoxifen group compared with the exemestane group
(Table 5). Twenty-ﬁve endometrial cancers have been reported:
nine in the exemestane group (four on treatment and ﬁve after
treatment) and 16 in the tamoxifen group (nine on treatment
and seven after treatment) although this difference was not
signiﬁcant [24].
discussion
The IES endometrial sub-protocol is the ﬁrst randomised,
double-blind study to investigate the sonographic endometrial
effects of a switch to exemestane after initial tamoxifen as an
adjuvant treatment of early breast cancer. Participants in the
sub-protocol were postmenopausal (median 12 years since last
Table 1. Patient and tumour characteristics at study entry
Exemestane (N = 87) Tamoxifen (N = 96)
n % n %
Age (years)
<60 37 42.5 41 42.7
60–69 35 40.2 42 43.8
70+ 15 17.2 13 13.5
Nodal status
Negative 47 54.0 56 58.3
1–3 nodes positive 26 29.9 21 21.9
4+ nodes positive 11 12.6 16 16.7
Missing/unknown 3 3.5 3 3.1
Hormone receptor status
ER positive; PgR positive 35 40.2 41 42.7
ER positive; PgR negative/
unknown
35 40.2 25 26.0
ER unknown; PgR
positive/unknown
12 13.8 21 21.9
ER negative; PgR positive 0 0.0 2 2.1
ER negative; PgR negative/
unknown
5 5.8 7 7.3
Tumour size
<2 cm 35 40.2 34 35.4
2–5 cm 47 54.0 53 55.2
>5 cm 3 3.5 5 5.2
Missing 2 2.3 4 4.2
Tumour grade
G1 10 11.5 14 14.6
G2 38 43.7 49 51.0
G3 14 16.1 17 17.7
Undifferentiated 1 1.2 1 1.0
Not assessable 8 9.2 3 3.1
Missing/unknown/not
assessed
16 18.4 12 12.5
Histological type
Inﬁltrating lobular 13 14.9 8 8.3
Inﬁltrating ductal 65 74.7 77 80.2
Other 9 10.3 11 11.5
Type of surgery
Mastectomy 64 73.6 64 66.7
Wide local excision 17 19.5 24 25.0
Other 6 6.9 8 8.3
Prior chemotherapy use 43 49.4 50 52.1
Duration of prior tamoxifen
(months)
Median (IQR) 26.8 (25.1–31.7) 28.1 (25.6–32.4)
Weight at baseline (kg)
Mean (SD) 72.0 (14.4) 72.8 (11.6)
Years since last menses
Median (IQR) 13.0 (4.5–17.5) 11.8 (5.3–16.3)
Prior HRT use 15 17.2 11 11.5
ER, estrogen receptor; PgR, progesterone receptor; IQR, inter-quartile
range; SD, standard deviation; HRT, hormone replacement therapy.
Table 2. ET and uterine volume at baseline
Exemestane Tamoxifen
ET (mm)
N 84 95
Median 5.8 6.0
IQR 3.2–9.4 4.0–9.0
Uterine volume (cm
3)
N 80 92
Median 38.4 44.2
IQR 24.9–61.6 31.1–60.6
ET, endometrial thickness; IQR, inter-quartile range.
Table 3. Proportion of patients with ET ‡5 mm (ITT population)
Visit Exemestane Tamoxifen Chi-square
P value N ET ‡5 mm (%) N ET ‡5 mm (%)
Baseline 84 52 (61.9) 95 60 (63.2) 0.86
6 months 69 30 (43.5) 69 45 (65.2) 0.01
12 months 61 19 (31.2) 61 35 (57.4) 0.004
24 months 62 22 (35.5) 55 34 (61.8) 0.004
a
EoT 54 15 (27.8) 53 33 (62.3) <0.001
EoT + 12
months
52 16 (30.8) 49 17 (34.7) 0.67
EoT + 24
months
46 16 (34.8) 38 13 (34.2) 0.96
aProportion of patients with ET ‡5 mm at 24 months in the evaluable for
primary end point population was identical to those in the ITT population.
ET, endometrial thickness; EoT, end of treatment.
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randomisation, 63% had abnormal ET on TVUS, likely as
a consequence of the previous 2–3 years of tamoxifen
treatment. Switching to exemestane resulted in a signiﬁcant
decrease of ET: 51% of patients with abnormal ET at baseline
had normal ET 24 months after switch. Uterine volume also
signiﬁcantly decreased after the switch. Patients randomised to
continue on tamoxifen had no signiﬁcant variations in ET or
uterine volume until the completion of adjuvant hormone
therapy.
Studies on the endometrial effects of switching to an AI
after tamoxifen have indicatedar e d u c t i o no fE Ta s s o c i a t e d
with AI treatment [28–32]. However, the follow-up period in
these studies did not extend to the post-treatment phase,
thus the effects of tamoxifen cessation (in the absence of an
AI) could not be assessed and compared with those of
switching to AIs. In the IES, patients were prospectively
followed for 2 years after the end of adjuvant hormone
treatment. After the end of treatment, patients in the
tamoxifen group obtained reductions in ET and uterine
volume paralleling those observed in the exemestane group
during the treatment phase. This indicates that the reduction
of ET and uterine volume seen after switching to exemestane
is largely due to cessation of the stimulatory effect of
tamoxifen. Approximately one-third of the patients in both
groups still had abnormal ET up to 2 years after the end of
treatment, which equates to >4 years after withdrawal of
tamoxifen in the exemestane group. Other reports on the
effects of tamoxifen discontinuation show a reduction in
mean ET after cessation of treatment, with a signiﬁcant
proportion of patients still having abnormal ﬁndings during
follow-up [14–16].
It is unknown how many of the patients participating in our
study had abnormal ET before starting adjuvant hormone
therapy. While in a population of healthy postmenopausal
women not on HRT the incidence of abnormal ET is expected
to be low, among women with breast cancer, other factors, such
as relative hyperestrogenism, may play a role and lead to
endometrial stimulation independently of tamoxifen. In the
ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial
comparing 5 years of adjuvant treatment with tamoxifen with 5
years of anastrozole or the combination, the baseline incidence
of endometrial thickening (ET > 5 mm) among 260 patients
participating in the endometrial sub-protocol was 21% [33]. In
another study on 146 breast cancer patients scheduled to start
adjuvant tamoxifen, baseline TVUS revealed thickened
endometrium (‡5 mm) in 30% of cases [34]. Post-treatment
data have not been reported for these studies.
The management of early breast cancer patients on
hormone therapy represents a signiﬁcant proportion of the
workload of many oncologists: gynaecological side-effects of
tamoxifen are a frequent occurrence and often result in
additional investigations, procedures and referrals. As
switching to exemestane results in a signiﬁcant reduction in
gynaecological problems, this approach may have potentially
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Figure 2. (A) Mean change [95% conﬁdence interval (CI)] in endometrial
thickness from baseline. (B) Mean change (95% CI) in uterine volume
from baseline.
Table 4. Transition between abnormal (‡5 mm) and normal ET after 24 months of randomised treatment
Exemestane Tamoxifen
N
a Normal ET
at 24 months,
n (%)
Abnormal
ET (‡5 mm)
at 24 months, n (%)
N Normal ET
at 24 months,
n (%)
Abnormal ET
(‡5 mm) at
24 months, n (%)
Normal ET at baseline 23 19 (83) 4 (17) 23 15 (65) 8 (35)
ET (‡5 mm) at baseline 38 20 (53) 18 (47) 32 6 (19) 26 (81)
aBaseline TVUS unavailable for one patient.
ET, endometrial thickness; TVUS, transvaginal ultrasound.
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decrease of ET and uterine volume was seen with exemestane,
whereas in patients continuing on tamoxifen, ultrasound
abnormalities tend to persist until treatment completion. This
is consistent with the reductiono fg y n a e c o l o g i c a la d v e r s e
events observed in the main IES trial.
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Table 5. Number of gynaecological/menopausal adverse events reported on treatment (in whole IES population)
Adverse event Exemestane (N = 2320) Tamoxifen (N = 2338) P value
All CTC grades UG Total % All CTC grades UG Total %
Gynaecological symptoms 128 128 256 11.0 156 210 366 15.7 <0.001
Serious gynaecological
symptoms
70 55 125 5.4 90 103 193 8.3 <0.001
Endometrial hyperplasia 0 1 1 0.0 1 19 20 0.9 <0.001
Genital pruritis female 19 0 19 0.8 21 7 28 1.2 0.2
Hot ﬂashes 955 2 957 41.3 901 2 903 38.6 0.07
Hysterectomy 0 17 17 0.7 0 25 25 1.1 0.22
Uterine D&C 0 12 12 0.5 0 29 29 1.2 0.01
Uterine polyps/ﬁbroids 1 23 24 1.0 1 64 65 2.8 <0.001
Vaginal discharge 53 12 65 2.8 79 12 91 3.9 0.04
Vulvovaginal dryness 53 2 55 2.4 47 4 51 2.2 0.67
Metrorrhagia/vaginal
bleeding
80 23 103 4.4 116 42 158 6.8 0.002
Vaginal prolapse/uterine
prolapse
4 23 27 1.2 2 11 13 0.6 0.02
Vaginitis/vaginitis atrophic/
vaginal candidiasis/vaginal
infection
13 27 40 1.7 12 28 40 1.7 0.97
Serious gynaecological events and menopausal symptoms are presented if the incidence is ‡10% in either treatment group, if the difference between the
groups is >1% or if the difference between treatment groups resulted in a P value of <0.01. Patients with prior hysterectomy were excluded from the
denominator for uterine polyps, ﬁbroids, D&C, endometrial cancer and hysterectomy.
IES, Intergroup Exemestane Study; CTC, Common Toxicity Criteria; UG, ungraded (classed as between grades 2 and 3); D&C, dilation and
curettage.
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